For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06868277?term=artemide-lung04&limit=10&sort=@relevance&rank=1
ARTEMIDE-Lung04: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (D702GC00001)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Pulmonary
Study Status:
Open to Accrual
Principal investigator:
Mei Tang, MD
IRB number :
2270783
Study Number:
G2501
Phone:
Fax:
ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Robert Donegan, MD
IRB number :
2094429
Study Number:
G2309
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05633654
C6461003: An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Bevacizumab in Combination with Chemotherapy in Treatment-Naive Participants with Metastatic Colorectal Cancer
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gastrointestinal
Study Status:
Open to Accrual
Principal investigator:
Gang Chen, MD, PhD
IRB number :
2386625
Study Number:
G2513
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT07222800?term=C6461003&viewType=Card&limit=10&sort=@relevance&rank=1
CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Kruti Patel, MD
IRB number :
1434853
Study Number:
CCTG MA.39
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT03488693
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)
Contact Name:
Laura Morse Cucci
Study Type:
Oncology - Gastrointestinal
Study Status:
Open to Accrual
Principal investigator:
Gang Chen, MD, PhD
IRB number :
2346030
Study Number:
G2506
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06467357?term=destiny-biliary&rank=2